Nucleosides and emerging viruses: A new story
Related Experiment Video
Updated: Oct 3, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Vincent Roy1, Luigi A Agrofoglio1
1ICOA, University of Orléans, CNRS UMR 7311, Rue de Chartres, 45067 Orléans, France.
Abstract:
With several US Food and Drug Administration (FDA)-approved drugs and high barriers to resistance, nucleoside and nucleotide analogs remain the cornerstone of antiviral therapies for not only herpesviruses, but also HIV and hepatitis viruses (B and C); however, with the exception of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for which vaccines have been developed at unprecedented speed, there are no vaccines or small antivirals yet available for (re)emerging viruses, which are primarily RNA viruses. Thus, herein, we present an overview of ribonucleoside analogs recently developed and acting as inhibitors of the viral RNA-dependent RNA polymerase (RdRp). They are new lead structures that will be exploited for the discovery of new antiviral nucleosides.
Related Concept Videos
Viruses with RNA Genomes
Size and Structure of Viral Genomes
Introduction to Virus
Viral Mutations
Subviral Agents
Retrovirus Life Cycles

